SEC Filing Document

Company: DUKE Robotics Corp.
Ticker: DUKR
CIK: 1638911
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-12-22
Accession Number: 0001213900-25-124553
Exchange: OTC
SIC Code: 3721
SIC Description: Aircraft
URL: https://www.sec.gov/Archives/edgar/data/1638911/000121390025124553/filename1.htm

Chunk 15 of 51
Word Count: 1489
Character Count: 9189

Document Content:

be granted under our existing equity incentive plans; and ● [____] shares of common stock issuable upon the exercise of the Representative’s Warrants to be issued in this offering. DETERMINATION OF OFFERING PRICE The offering price of the Units has been negotiated between us and the Representative. Among the factors considered in determining the public offering price of the Units, including the exercise price of the warrants were: ● our history and our prospects; ● the industry in which we operate; ● our past and present operating results; ● the anticipated market price of our common stock following this offering, the expected volatility of our common stock, the terms of the warrants (including their duration and exercise mechanics), and the likelihood that the warrants would be exercised; ● the previous experience of our executive officers; and ● the general condition of the securities markets at the time of this offering.

The offering price stated on the cover page of this prospectus should
not be considered an indication of the actual value of the Units sold in this offering, the exercise price of the warrants, or the shares
of common stock or warrants included in such Units. The values of such securities are subject to change as a result of market conditions
and other factors.

MARKET FOR OUR COMMON STOCK

Our common stock is quoted
on the OTCQB under the trading symbol “DUKR.” Quotations on the OTCQB reflect inter-dealer prices, without retail mark-up,
mark-down commission, and may not represent actual transactions. On [_], 2025, the last reported sale price of our common stock was $[_]
per share.

Holders

As of [_], 2025, we had approximately
[_] shareholders of record of our common stock.

Dividend Policy

We have never paid or declared
any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.
We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination
to pay dividends will be at the discretion of our Board and will depend upon a number of factors, including our results of operations,
financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our Board deems
relevant.

Equity Compensation Plan Information

On May 27, 2021, our Board
of Directors approved the 2021 Plan, pursuant to which we may issue awards, from time to time, consisting of non-qualified stock options,
restricted stock grants and restricted stock units (“RSUs”). In addition, stock option awards that qualify under Section 102
of the Israeli Tax Ordinance (New Version) 1961 (the “ITO”), and/or under Section 3(i) of the ITO, may be granted. A summary
of the 2021 Plan is found below.

Under the 2021 Plan, options, restricted share and RSUs may be granted
to our officers, directors, employees and consultants or the officers, directors, employees and consultants of our subsidiary. On March
18, 2025, our Board approved an increase in the amount of shares of common stock available under the 2021 Plan from 4,800,000 to 9,000,000.
To the extent that an award lapses or is forfeited, the shares subject to such Award will again become available for grant under the terms
of the 2021 Plan.

We do not have any formal
policy that requires the Company to grant, or avoid granting, equity-based compensation at certain times. We do not grant equity awards
in anticipation of the release of material nonpublic information that is likely to result in changes to the price of our common stock,
and do not time the public release of such information based on award grant dates. The timing of any equity grants to executive officers
or directors in connection with new hires, promotions, or other non-routine grants is tied to the event giving rise to the award (such
as an executive officer’s commencement of employment or promotion effective date).

On March 18, 2025, our Board approved the following grants: (i) 1,000,000
options to purchase shares of common stock to Mr. Yossef Balucka, our CEO; (ii) 500,000 options to purchase shares of common stock to
Mr. Vadim Maor, our CTO, (iii) 120,000 options to purchase shares of common stock to Ms. Gousman, our newly appointed Director, (iv) 400,000
options to purchase shares of common stock to Mrs. Alexandra Papaconstantinou the appointed Managing Director of Duke Greece, (v) 50,000
options to purchase shares of common stock to Mr. Shlomo Zakai, our CFO.

The following table summarizes
certain information regarding our equity compensation plans as of December 31, 2024:

Plan Category Number of securities to be issued upon exercise of outstanding options Weighted-average exercise price of outstanding options Number of securities remaining available for future issuance under equity compensation plans

Equity compensation plan not approved by security holders 2,426,812 0.81 2,373,188

No Loans for Option Exercises.
It is our policy to not make loans to employees or officers for the purpose of paying for the exercise of stock options.

DILUTION

If you invest in our Units
in this offering, your interest will be diluted to the extent of the difference between the public offering price per share of common
stock that is part of the Unit and the as adjusted net tangible book value per share of common stock immediately after this offering.

Our net tangible book value
is the amount of our total tangible assets less our total liabilities. Our net tangible book value as of September 30, 2025 was $222,000,
or approximately $0.0041 per share of common stock. Net tangible book value per share represents our total tangible assets less total
liabilities, divided by the number of shares of common stock outstanding.

As adjusted net tangible book
value is our net tangible book value after taking into account the effect of the sale of Units in this offering, and not giving effect
to any shares to be issued in the Short-Form Merger, at the public offering price of $[____] per Unit and after deducting the underwriting
discounts and commissions and other estimated offering expenses payable by us. Our as adjusted net tangible book value as of September
30, 2025 would have been approximately $[_______], or $[_______] per share. This amount represents an immediate increase in as adjusted
net tangible book value of approximately $[_______] per share to our existing stockholders, and an immediate dilution of $[_______] per
share to new investors participating in this offering. Dilution per share to new investors is determined by subtracting as adjusted net
tangible book value per share after this offering from the public offering price per Unit paid by new investors.

The following table illustrates
this per share dilution:

Public offering price per share (attributing no value to the warrants) $

Net tangible book value per share as of September 30, 2025 $	0.0041

Increase in as adjusted net tangible book value per share after this offering $

As adjusted net tangible book value per share after giving effect to this offering $

Dilution in as adjusted net tangible book value per share to new investors $

A [50]% increase (decrease)
in the public offering price of $[____] per Unit would increase (decrease) the as adjusted net tangible book value per share by $[_______]
($[_______]), and the dilution per share to new investors in this offering by $[_____] ($[____]), assuming the number of Units offered
by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us.

The following table summarizes
as of September 30, 2025, on an as-adjusted basis and giving effect to the sale of all Units offered to the investors in this offering,
as described above, the number of shares of common stock, the total consideration and the average price per share (1) paid to us by our
existing stockholders and (2) to be paid by investors purchasing Units in this offering at a public offering price of $[__] per Unit,
before deducting underwriting discounts and commissions and estimated offering expenses payable by us:

Shares Purchased Total Consideration Average Price

Number Percent Amount Percent Per Share

Existing stockholders [___] [___]	% $	[___] [___]	% $	[___]

New investors [___] [___]	% [___] [___]	% [___]

Total [___] 100.0	% $	[___] 100.0	% $	[___]

The information above assumes
that the Representative does not exercise its over-allotment option. If the Representative exercises its over-allotment option in full,
the as adjusted net tangible book value will increase to $[____] per share, representing an immediate increase to existing stockholders
of $[____] per share and an immediate dilution of $[_____] per share to new investors.

The foregoing discussion and
table do not take into account further dilution to new investors that could occur upon the exercise or conversion of outstanding warrants,
and options, having a per share exercise or conversion price less than the per share offering price to the public in this offering.